Treatment gaps remain for older patients with HFrEF, according to results published in the European Journal of Heart Failure. Gianluigi Savarese, MD, and colleagues found that use of renin-angiotensin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists were, respectively, 80%, 88%, and 35% in patients 80and older, and 95%, 95%, and 54% in those younger than 70. Defibrillator and cardiac resynchronization therapy usage rates were, respectively, 7% and 23% in those 80 and older, and 29% and 50% in those younger than 70.